Medical Advisory Board
Dr. Mark M. Souweidane is Director of Pediatric Neurosurgery at New York-Presbyterian-Komansky Children’s Hospital and Memorial Sloan-Kettering Cancer Center. He is the Vice Chairman of the Department of Neurological Surgery at Weill Cornell Medical College. His primary career objective has been to improve the outcome for children with primary central nervous system tumors, including diffuse intrinsic pontine glioma (DIPG).
Dr. Souweidane’s research is focused on enhancing drug delivery to the brain and brain tumors of children. Specifically, the Souweidane laboratory is testing a form of direct delivery called convection-enhanced delivery (CED) towards the treatment of DIPG. This work translated into a Phase I clinical trial, “Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy” (P.I.: M.M. Souweidane, NCT01502917). The trial began enrolling patients in May of 2012 at Memorial Sloan Kettering Cancer Center and remains open for patient accrual. Through the Pediatric Brain Cancer Tumor Consortium (PBTC) it is expected that this innovative clinical trial will be offered across North America in the forthcoming year.
Dr. Souweidane is the co-director the Weill Cornell Children’s Brain Tumor Project (CBTP) and a member of the Meyer Cancer Center at Weill Cornell Medicine. Dr. Souweidane chairs the neurosurgery committee and is on the steering committee of the Children’s Oncology Group (COG). This year he was named to the NCI’s Brain Malignancy Steering Committee.
Dr. Souweidane completed his undergraduate training at the University of Michigan, where he graduated with honors in Microbiology. He attended Wayne State University Medical School as a member of the Alpha Omega Alpha Honor Society. He completed his general surgery internship at University of Michigan Hospitals and subsequently did his neurosurgery residency at New York University under the direction of Drs. Joseph Ransohoff and Fred Epstein. Dr. Souweidane completed his fellowship pediatric neurosurgery at the Hospital for Sick Children in Toronto, Canada.
Oren J. Becher, MD
Dr. Oren J. Becher is a pediatric neuro-oncologist who has dedicated his career to improving therapies for children with brain and spinal cord tumors with a particular focus on identifying effective therapies for children with DIPG. He is both a physician and a scientist, spending time caring for children with cancer and leading a research laboratory. He has received numerous prestigious awards and is on the advisory board for several foundations including the Cristian Rivera Foundation.
Dr. Oren J. Becher completed his undergraduate training at the University of Pennsylvania where he graduated Magna Cum Laude with a double major in biochemistry and economics. He subsequently attended the Johns Hopkins School of Medicine. It was during his years at Johns Hopkins that Dr. Becher realized his passion to care for children with cancer. He then went on to complete a pediatric residency at the Children’s National Medical Center in Washington D.C. This is where he began research on pediatric brain tumors. Dr. Becher then moved to NY to pursue a fellowship in Pediatric Hematology-Oncology at Cornell/Memorial Sloan-Kettering Cancer Center.
Dr. Oren Becher has made several important discoveries, including the development of the first genetically engineered mouse model for DIPG. While at MSKCC, he also initiated two clinical trials for children with recurrent solid tumors. Afterward, Dr. Becher focused on identifying promising therapies to translate into clinical trials for children with DIPG at the Ann & Robert H. Lurie Children’s Hospital and the Lurie Cancer center at Northwestern University where he was an associate professor in the department of Pediatrics. He is currently the Chief of Pediatric Hematology-Oncology at Mount Sinai Kravis Children’s Hospital.